|
| Press Releases |
|
 |
|
| Thursday, July 25, 2024 |
|
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
| Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Tuesday, July 16, 2024 |
|
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社（本社：東京都、以下 佐藤製薬）と締結したことをお知らせします。 more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「レケンビ」（レカネマブ）がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ®」（一般名：レカネマブ）について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「LEQEMBI」（レカネマブ）が香港においてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性 アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（香港製品名：「樂意保(R)」、一般名：レカネマブ）について、香港衛生署（Department of Health）より新薬承認を取得したことをお知らせします。 more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025 23:29 HKT/SGT
|
|
|
Global Leaders Gather for XIII International Meeting on International Cooperation
May 28, 2025 21:30: JST
|
|
|
Modern Dental Group's Thai Subsidiary Hexa Ceram Held 30th Anniversary Celebration and Dental Symposium
May 28, 2025 21:30 HKT/SGT
|
|
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025 20:57: JST
|
|
|
Global Leaders Gather for XIII International Meeting on International Cooperation
May 28, 2025 20:30 HKT/SGT
|
|
|
SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign "Life's too Short, You Gotta Chew" at THAIFEX - ANUGA ASIA 2025
May 28, 2025 18:00 HKT/SGT
|
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28, 2025 17:45 JST
|
|
|
現代牙科集團泰國公司Hexa Ceram舉辦三十周年慶典暨牙科論壇
May 28, 2025 16:30 HKT/SGT
|
|
|
现代牙科集团泰国公司Hexa Ceram举办三十周年庆典暨牙科论坛
May 28, 2025 16:12 HKT/SGT
|
|
|
三菱重工、2024事業計画推進状況について発表
May 28, 2025 16:05: JST
|
|
|
GK Software becomes a Fujitsu company
May 28, 2025 15:33 JST
|
|
|
GMG Announces Internal G(R) Lubricant Testing Results Showing 10% Fuel Savings and 33% Reduction in Particulate Emissions
May 28, 2025 08:29 HKT/SGT
|
|
|
Spotlight: Sunny Nandwani, Founder & CEO, Acuver Consulting Inc.
May 27, 2025 22:30 HKT/SGT
|
|
|
聯想控股旗下君聯資本及聯想之星共同投資企業派格生物醫藥在港交所成功上市
May 27, 2025 22:10 HKT/SGT
|
|
|
联想控股旗下君联资本及联想之星共同投资企业派格生物医药在港交所成功上市
May 27, 2025 21:41 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
